{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:56:58Z","timestamp":1785182218435,"version":"3.55.0"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The Antiretroviral Pregnancy Registry (APR) is designed to detect major teratogenic effects of antiretroviral medications; other pregnancy outcomes are also recorded when reported. We compared available pregnancy and birth outcomes of women exposed to oral rilpivirine\u2010containing regimens (oral\u2010RPV cohort) versus non\u2010rilpivirine regimens (non\u2010RPV cohort) over the period 2011 to 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Maternal age\u2010adjusted prevalence ratio (aPR) of pregnancy and birth outcomes was compared for prospectively reported pregnancies; aPR of birth defects was compared between first\u2010trimester exposures and combined second\/third\u2010trimester exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 6937 pregnancies were recorded, including 4617 (oral\u2010RPV cohort, 781 [16.9%]; non\u2010RPV cohort, 3836 [83.1%]) from the United States. Among live births, the prevalence of birth defects was lower in the oral\u2010RPV cohort (1.6% versus 3.8%; aPR: 0.4 [95% confidence interval (CI): 0.2\u20130.8]). The prevalence of birth defects in the first\u2010trimester oral\u2010RPV exposure versus second\/third\u2010trimester exposure did not differ (aPR: 3.4 [95% CI: 0.4\u201326.3]). The aPR of induced abortions (1.1 [0.6\u20131.9]), stillbirths (0.6 [0.2\u20131.6]) and premature birth (0.8 [0.7\u20131.1]) were similar between cohorts. Prevalences for spontaneous abortion were 5.8% (oral\u2010RPV cohort) versus 3.2% (non\u2010RPV cohort) below the expected background rate (15%\u201320%). Low birth weights were less reported in oral\u2010RPV, while very low birth weights were similar between cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Review of available data from the APR does not indicate an association between adverse pregnancy or birth outcomes and oral\u2010RPV exposure, overall or by timing of exposure. Since APR targets primarily teratogenic effects, findings for non\u2010teratogenic effects should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70112","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T06:06:27Z","timestamp":1757657187000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating birth outcomes following oral rilpivirine use in pregnancy in the\n                    <scp>United States<\/scp>\n                    : Findings from the antiretroviral pregnancy registry"],"prefix":"10.1111","volume":"27","author":[{"given":"William R.","family":"Short","sequence":"first","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-6019","authenticated-orcid":false,"given":"Corinne","family":"Willame","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Syneos Health  Morrisville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7884-7983","authenticated-orcid":false,"given":"Ping","family":"Xu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Birmingham","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Van Solingen\u2010Ristea","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Baugh","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"WHO.Mother\u2010to\u2010child transmission of HIV.https:\/\/www.who.int\/teams\/global\u2010hiv\u2010hepatitis\u2010and\u2010stis\u2010programmes\/hiv\/prevention\/mother\u2010to\u2010child\u2010transmission\u2010of\u2010hiv. Accessed 15 December 2023"},{"key":"e_1_2_10_3_1","unstructured":"NCHHSTP AtlasPlus.Prevention UCfDCa.2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0033354920935074"},{"key":"e_1_2_10_5_1","unstructured":"Association. AP.Pregnancy Complications HIV\/AIDS During Pregnancy.http:\/\/americanpregnancy.org\/pregnancy-complications\/hiv-aids-during-pregnancy\/. Accessed 4 February 2024"},{"key":"e_1_2_10_6_1","unstructured":"ClinicalinfoHIV.gov.Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States.2023https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal\/recommendations-arv-drugs-pregnancy-overview. Accessed 15 December 2023"},{"key":"e_1_2_10_7_1","unstructured":"US Department of Health and Human Services.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.2024https:\/\/clinicalinfo.hiv.gov\/en\/guidelines. Accessed 4 April 2024"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22246"},{"key":"e_1_2_10_9_1","unstructured":"Rilpivirine (Edurant) [package insert].2022https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/202022s017s018lbl.pdf. Accessed 8 January 2023"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0184-8"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000968"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix534"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.982"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.971"},{"key":"e_1_2_10_15_1","unstructured":"Metropolitan Atlanta Congenital Defects Program (MACDP). 2018bPrevention CfDCa.https:\/\/www.cdc.gov\/ncbddd\/birthdefects\/macdp.html. Accessed 4 February 2024."},{"key":"e_1_2_10_16_1","unstructured":"Services. TDoSH. Texas Birth Defects Epidemiology & Surveillance.Monitor Vol 28.2018https:\/\/www.dshs.texas.gov\/sites\/default\/files\/birthdefects\/monitor\/Monitor%20Vol%2028.pdf. Accessed 4 February 2024"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.01.047"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T10:55:49Z","timestamp":1767351349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/hiv.70112"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70112","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"2025-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}